Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

A Phase 3, Open-Label, Single-Arm, Multicenter Study to Evaluate Ravulizumab Administered Intravenously in Pediatric Patients With Anti-Acetylcholine Receptor Antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG)